# Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

> **NCT01753557** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 54 (actual)

## Conditions studied

- Chronic Hepatitis C (CHC)

## Interventions

- **DRUG:** MP-424
- **DRUG:** RBV
- **DRUG:** PEG-IFN alfa-2a

## Key facts

- **NCT ID:** NCT01753557
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753557, "Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01753557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*